6,365
51
Early phase trial suggests PARP inhibitor combination show promise in treating hard to treat patients with SCLC
Tagrissio, Tarceva and other TKI therapy for EGFR + NSCLC continue to evolve and improve survival.
FDA Approval of Rozlytrek & Vitrakvi shifts cancer treatment toward genomic testing - 3rd tissue agnostic drug approved
FDA Approves Rozlytrek for Treatment of ROS 1 NSCLC
Inrebic represents a new treatment option for Jakafi-resistant Myelofibrosis
Ocular melanoma is an uncommon cancer of the eye requiring aggressive treatment by specialized physicians.
Lynparza is an effective treatment for women with newly diagnosed and recurrent BRCA + and other mutated ovarian cancers
Understand all the treatment options for advanced kidney or renal cell carcinoma.
Amgen releases initial data on AMG 420 Immunotherapy and the initial results in multiple myeloma look very good
Photodynamic therapy for neck cancer - good overview. Anyone have experience? …
Has anyone elected to receive triple drug therapy and delay their ASCT? Seems like there is…
Several trials for GBM and other brain cancers at MSKCC: they keep them updated here:…
Tarceva™ Improves Survival in Non-Small Cell Lung Cancer
New precision cancer medicine trials for brain tumors at UCSF:…
What have others experience been using ice chips to reduce mouth pain and mucositis? A new study…
What have you found that helps with neuropathy?…
Neuropathy (Numbness and Tingling )- How is it Prevented and Treated?
Looking for women living with breast cancer for research study. The goal is to get your opinions…
First NET Center of Excellence Recognized:…
